Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives [0.03%]
精准使用中国卵巢癌PARP抑制剂：临床进展、耐药机制及未来展望
Jing Yu,Maochen Li,Yuhan Zhu et al.
Jing Yu et al.
Antibiotics and probiotics differentially shape immunotherapy outcomes in non-small cell lung cancer [0.03%]
抗生素和益生元通过不同机制影响非小细胞肺癌免疫疗法的疗效
Shuling Ma,Zijun Zhai,Rui Ding et al.
Shuling Ma et al.
Comprehensive microbiome profiling reveals mucosal microbiome heterogeneity in patients with left- and right-sided colorectal neoplasia [0.03%]
全面的微生物组谱分析揭示了左、右结直肠肿瘤患者黏膜微生物组的异质性
Sunny H Wong,Thomas N Y Kwong,Ru Zhang et al.
Sunny H Wong et al.
Objective: Left- and right-sided colorectal cancer (CRC) exhibit distinct molecular and clinicopathologic features. However, little is known about the spatial heterogeneity of microbial signatures. In this study the profi...
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH) [0.03%]
一线奥希替尼治疗中国EGFR突变阳性晚期非小细胞肺癌患者的有效性和安全性：一项前瞻性、多中心、非干预性研究（FLOURISH）
Lisha Shen,Dongqing Lv,Ke-Jing Tang et al.
Lisha Shen et al.
Objective: Osimertinib has demonstrated superior efficacy as a first-line treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) in clinical trials. This study was aimed at provid...
Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy [0.03%]
微生物介导的免疫性细胞死亡重编程：肿瘤免疫治疗的新范式
Yilin Li,Huiyue Zhang,Yun Feng et al.
Yilin Li et al.
Immunogenic cell death (ICD), a special form of cell death, transforms "cold" tumors into "hot" tumors by fulfilling the following three key conditions: antigenicity; adjuvanticity; and a suitable tumor microenvironment (TME). Tumor cells r...
Xiaofei Jiao,Yiyang Shen,Yixuan Tang et al.
Xiaofei Jiao et al.
T cell activity is fundamental to effective immunotherapies and sustained tumor control. Recent studies have demonstrated that the therapeutic potential of T cells is notably affected by DNA damage dynamics. Notably, DNA damage within T cel...
Ferumoxytol triggers cancer ferroptosis via an NF-κB-driven IRONKILL mechanism [0.03%]
富马氧托尔通过NF-κB驱动的IRONKILL机制触发癌症铁依赖性细胞死亡（ Ferroptosis）
Tao Luo,Meng Li,Shijie Zhang et al.
Tao Luo et al.
HBx-mediated GPT2 suppression promotes liver cancer development by downregulating ADH1A [0.03%]
Hbx通过下调Adh1a抑制Gpt2促进肝癌发生发展
Hongjuan You,Xing Wang,Ruyu Liu et al.
Hongjuan You et al.
Objective: Hepatitis B virus (HBV) is the primary driver of liver cancer (LC), a malignancy characterized by extensive metabolic reprogramming. However, the specific mechanisms linking viral oncoproteins to metabolic dysr...
CAMK2D isoform 15 facilitates gefitinib resistance via AKT phosphorylation in lung adenocarcinoma [0.03%]
CAMK2D的第15种亚型通过AKT磷酸化促进肺腺癌细胞对吉非替尼产生耐药性
Lingmei Li,Danyang Ren,Yutian Wang et al.
Lingmei Li et al.
Objective: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is a major challenge in the treatment of lung adenocarcinoma (LUAD). Our previous study demonstrated that EGFR sign...
VAMP2/SNAP25 promotes the aggressive progression of head and neck cancer by regulating the fate of multivesicular bodies [0.03%]
VAMP2/SNAP25通过调节多囊体的命运促进头颈部肿瘤的侵袭性发展
Suwen Bai,Hexing Sun,Rong Liu et al.
Suwen Bai et al.
Objective: Tumor-secreted exosomes are essential in driving tumor progression by releasing multivesicular bodies (MVBs), which are endosome organelles containing intraluminal vesicles (ILVs), as exosomes. However, the mec...